FDA Guts Fish Oil Pills’ Reg Strategy: Nixes Longer Exclusivity For Vascepa, Revised Listing For Lovaza
This article was originally published in The Pink Sheet Daily
Executive Summary
Amarin says it may challenge FDA’s decision on Vascepa exclusivity; Crowell & Moring had wanted a reduced dose of Lovaza listed in the Orange Book.